Transaction in own shares
GSK plc (the " Company ") announces today acting through its corporate stockbroker, Merrill Lynch International (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.
| Date of purchase: |
18 July 2025 |
| Aggregate number of ordinary shares of 31¼ pence each purchased: |
505,771 |
| Lowest price paid per share (GBp): |
1,319.00p |
| Highest price paid per share (GBp): |
1,360.50p |
| Volume-weighted average price paid per share (GBp): |
1,344.42p |
The purchased shares will be held as Treasury shares.
Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 14,683,084 ordinary shares.
Following the above purchase, the Company will hold 232,817,467 ordinary shares in treasury and have 4,082,566,813 ordinary shares in issue (excluding Treasury shares).
The total number of voting rights in the Company is 4,082,566,813. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.70 per cent.
Detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme can be found at:
Ends
| GSK enquiries |
|
|
|
| Media: |
Tim Foley |
+44 (0) 20 8047 5502 |
(London) |
| |
Kathleen Quinn |
+1 202 603 5003 |
(Washington DC) |
| |
|
|
|
| Investor Relations: |
Constantin Fest |
+44 (0) 7831 826525 |
(London) |
| |
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
| |
Mick Readey |
+44 (0) 7990 339653 |
(London) |
| |
Steph Mountifield |
+44 (0) 7796 707505 |
(London) |
| |
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
| |
Frannie DeFranco |
+1 215 751 3126 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.